Non-alcoholic fatty liver disease（NAFLD） is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus（T2DM）, dyslipidemia, central obesity an...Non-alcoholic fatty liver disease（NAFLD） is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus（T2DM）, dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1（GLP-1） analogues and dipeptidyl peptidase-4（DPP-4） inhibitors were widely used to treat T2 DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor（GLP-1R） is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride（TG） content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and m RNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.展开更多
视黄醇结合蛋白4(retinol-binding protein 4,RBP4)属于视黄醇结合蛋白(RBP)家族中的分泌型RBP,主要在脂肪细胞和肝细胞分泌,在协助视黄醇发挥生理功能中起着不可替代的作用。研究人员于2005年发现RBP4是一种与胰岛素抵抗密切相关的新...视黄醇结合蛋白4(retinol-binding protein 4,RBP4)属于视黄醇结合蛋白(RBP)家族中的分泌型RBP,主要在脂肪细胞和肝细胞分泌,在协助视黄醇发挥生理功能中起着不可替代的作用。研究人员于2005年发现RBP4是一种与胰岛素抵抗密切相关的新的脂肪因子,从不同的环节参与了胰岛素抵抗的发生、发展。近年来研究发现RBP4参与了非酒精性脂肪性肝病、2型糖尿病、心血管疾病等的调节。深入研究RBP4在相关疾病的作用机制及关键靶点有着重要的意义,可为疾病的预防、诊疗及预后判断提供新的方向。本文就近年来RBP4在相关疾病的研究进展作一概述。展开更多
基金supported in part by grants from the National Basic Research Program of China(No.2012CB524900)Department of Science&Technology of Shandong Province,China(Nos.2012GSF11824 and 2011780)
文摘Non-alcoholic fatty liver disease（NAFLD） is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus（T2DM）, dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1（GLP-1） analogues and dipeptidyl peptidase-4（DPP-4） inhibitors were widely used to treat T2 DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor（GLP-1R） is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride（TG） content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and m RNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.
文摘视黄醇结合蛋白4(retinol-binding protein 4,RBP4)属于视黄醇结合蛋白(RBP)家族中的分泌型RBP,主要在脂肪细胞和肝细胞分泌,在协助视黄醇发挥生理功能中起着不可替代的作用。研究人员于2005年发现RBP4是一种与胰岛素抵抗密切相关的新的脂肪因子,从不同的环节参与了胰岛素抵抗的发生、发展。近年来研究发现RBP4参与了非酒精性脂肪性肝病、2型糖尿病、心血管疾病等的调节。深入研究RBP4在相关疾病的作用机制及关键靶点有着重要的意义,可为疾病的预防、诊疗及预后判断提供新的方向。本文就近年来RBP4在相关疾病的研究进展作一概述。
